Last reviewed · How we verify
L-alanyl-L-glutamine dipeptide
L-alanyl-L-glutamine dipeptide provides amino acid supplementation to support protein synthesis, immune function, and cellular metabolism, particularly in critically ill or post-operative patients.
L-alanyl-L-glutamine dipeptide provides amino acid supplementation to support protein synthesis, immune function, and cellular metabolism, particularly in critically ill or post-operative patients. Used for Nutritional support in critically ill patients, Post-operative metabolic support, Sepsis-associated malnutrition.
At a glance
| Generic name | L-alanyl-L-glutamine dipeptide |
|---|---|
| Also known as | Dipeptiven |
| Sponsor | National Cardiovascular Center Harapan Kita Hospital Indonesia |
| Drug class | Amino acid supplement / Nutritional agent |
| Modality | Small molecule |
| Therapeutic area | Critical Care / Intensive Care Medicine |
| Phase | Phase 3 |
Mechanism of action
This dipeptide is a conditionally essential amino acid combination that serves as a substrate for protein synthesis and glutamine-dependent cellular processes. It is used to maintain nitrogen balance and support immune function in patients with severe illness, sepsis, or major surgery where endogenous amino acid production is insufficient. The dipeptide formulation allows for improved stability and bioavailability compared to free glutamine.
Approved indications
- Nutritional support in critically ill patients
- Post-operative metabolic support
- Sepsis-associated malnutrition
Common side effects
- Hyperglycemia
- Electrolyte imbalance
- Gastrointestinal intolerance
Key clinical trials
- Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT) (PHASE2)
- Outcome of Perioperative Immune Enhancing Nutrition in Patients Undergoing Radical Cystectomy (NA)
- Role of Glutamine as Myocardial Protector in Elective On-Pump CABG Surgery With Low EF (PHASE3)
- Effect of Parenteral Glutamine on Myocardial Injury and Inflammation Biomarkers (NA)
- Effect of IV Alanyl Glutamine on Healing of Pressure Ulcers in Critically Ill Patients (NA)
- Impact of Perioperative Treatment With Intravenous Glutamine on Myocardial Protection in Cardiac Surgery Patients With Aortic Stenosis (NA)
- Efficacy and Mechanisms of GLN Dipeptide in the SICU (PHASE3)
- Safety and Efficacy of the Addition of Alanyl-Glutamine-Dipeptide to Dialysis Solution in Peritoneal Dialysis (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: